NCT02752646 - Tolerability and Toxicity of Topically Applied Nepafenac 0.3% vs Ketorolac 0.5% | Biotech Hunter

Enrollment

200

Participants

Timeline

Start Date

April 30, 2016

Primary Completion Date

March 1, 2017

Study Completion Date

March 1, 2017

Conditions

Cataract

Interventions

DRUG

nepafenac 0.3%

Patients in this group will receive nepafenac 0.3% eye drops once daily after cataract surgery.

DRUG

ketorolac

Patients in this group will receive ketorolac 0.5% eye drops four times daily after cataract surgery.

Trial Locations (2)

Cincinnati Eye Institute, Edgewood

Harvard Eye Associates, Laguna Hills